Current Rheumatology Reports最新文献_第8页

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-22 DOI: 10.1007/s11926-023-01128-3

Kevin Yip, Genna Braverman, Linda Yue, Theodore Fields

{"title":"Pipeline Therapies for Gout.","authors":"Kevin Yip, Genna Braverman, Linda Yue, Theodore Fields","doi":"10.1007/s11926-023-01128-3","DOIUrl":"10.1007/s11926-023-01128-3","url":null,"abstract":"Purpose of review: Despite effective available treatments, gout management is often unsuccessful in getting patients to target serum urate goal and in managing flares in the setting of comorbidities. Studies addressing future treatment options for short- and long-term management are reviewed.Recent findings: URAT-1 blocking agents have been helpful but have had limitations related to effects on renal function, lack of efficacy with renal impairment, and potential to increase renal stones. Dotinurad may function in the setting of decreased renal function. Arhalofenate has anti-URAT-1 activity and may also blunt gout flares. A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study. New uricase treatments manufactured in combination with agents that can reduce immunogenicity may make uricase treatment simpler. A unique strategy of inhibiting gut uricase may offer the benefits of avoiding systemic absorption. For gout flares, IL-1β inhibitor studies in progress include different dosing schedules. Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"69-80"},"PeriodicalIF":5.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temperature-Mediated Neural Interventions in Knee Osteoarthritis: a Review of Cryoneurolysis and Cooled Radiofrequency Ablation with Ultrasound Guidance. 膝关节骨性关节炎的温控神经干预：超声引导下的冷冻神经溶解术和冷却射频消融术综述。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-21 DOI: 10.1007/s11926-023-01127-4

Christopher M Tidwell, Paul J DeMarco

{"title":"Temperature-Mediated Neural Interventions in Knee Osteoarthritis: a Review of Cryoneurolysis and Cooled Radiofrequency Ablation with Ultrasound Guidance.","authors":"Christopher M Tidwell, Paul J DeMarco","doi":"10.1007/s11926-023-01127-4","DOIUrl":"10.1007/s11926-023-01127-4","url":null,"abstract":"Purpose of review: Knee osteoarthritis is a debilitating chronic disease affecting nearly half of the world's population at some point in their lives. Treatment of pain and loss of function associated with this disease has been limited. In this review, we seek to explore how neural interventions with ultrasound guidance may be an emerging option for non-pharmacologic pain relief in patients with knee osteoarthritis.Recent findings: Cryoneurolysis techniques have been demonstrated to provide pain relief out to 150 days post-treatment in knee osteoarthritis in select individuals. There have also been studies of cryoneurolysis pre-operatively to total knee replacement providing reduced pain, reduced opioid use post-operatively, and shorter hospital length of stay. Cooled radiofrequency ablation (CRFA) has been demonstrated to significantly reduce pain, improve functionality, and reduce pharmacologic needs in knee osteoarthritis out to 2 years. Both interventions appear to have increased accuracy with ultrasound, and CRFA appears to be associated with improved patient outcomes. The research demonstrates the efficacy of both cryoneurolysis and cooled radiofrequency ablation in the treatment of knee osteoarthritis. Ultrasound guidance in neurolysis provides an additional tool with real-time, high-accuracy nerve localization. These therapies should be considered for certain patients to assist in pain management in the non-operative and post-operative phase of knee osteoarthritis management. Further research is needed to further define the long-term effects and the long-term utility of the techniques in knee pain.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"89-95"},"PeriodicalIF":5.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings). SPARTAN 20 年：从开始到影响（SPARTAN 2023 年年会论文集）。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.1007/s11926-023-01131-8

Joerg Ermann, Atul Deodhar, Muhammad Asim Khan, Michael H Weisman, John D Reveille

引用次数: 0

Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review. 青少年皮肌炎中的钙质沉着——流行病学、发病机制、临床特征和治疗:系统综述。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI: 10.1007/s11926-023-01126-5

Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo

{"title":"Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review.","authors":"Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo","doi":"10.1007/s11926-023-01126-5","DOIUrl":"10.1007/s11926-023-01126-5","url":null,"abstract":"Purpose of review: We performed a systematic review of the literature on the epidemiology, pathogenesis, clinical and laboratory characterization, and treatment of calcinosis in patients with juvenile dermatomyositis (JDM). A qualitative systematic review was conducted from January 1975 to April 2023 according to the PRISMA protocol using three electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least one combination of the terms described in the search strategy appeared in the title, written in English, Portuguese, or Spanish, and addressed the epidemiology, pathogenesis, diagnosis, and treatment of calcinosis in juvenile dermatomyositis. Systematic or scoping reviews, letters, clinical images, book chapters, abstracts, inflammatory myopathy in other connective tissue diseases, idiopathic inflammatory myopathies in adults, and purely qualitative studies were excluded.Recent findings: Seventy-five studies were included. According to the literature, calcinosis is common in women, around five years old, with three years of disease in association with osteoarticular, cutaneous, pulmonary manifestations, and fever. The pathogenesis is still unknown, but the participation of interleukin 1 and 6, tumor necrosis factor alpha, and innate immunity dysregulation seem to be involved. Common autoantibodies are anti-NXP-2, anti-MDA-5, and anti-Mi-2, and their treatment remains controversial. Prospective, randomized, controlled studies are needed to evaluate treatment protocols and map the natural history of this serious complication. Calcinosis seems to be more common in White female children with muscle weakness, fever, arthritis, severe pulmonary, and skin involvement with anti-NXP-2, anti-MDA-5, and anti-Mi-2 autoantibodies. The multitargets and aggressive treatment is recommended.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"53-68"},"PeriodicalIF":5.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of IFN-α in Rheumatoid Arthritis. IFN-α 在类风湿关节炎中的作用

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-02-01 Epub Date: 2023-12-05 DOI: 10.1007/s11926-023-01125-6

Chung M A Lin, John D Isaacs, Faye A H Cooles

{"title":"Role of IFN-α in Rheumatoid Arthritis.","authors":"Chung M A Lin, John D Isaacs, Faye A H Cooles","doi":"10.1007/s11926-023-01125-6","DOIUrl":"10.1007/s11926-023-01125-6","url":null,"abstract":"Purpose of review: Type 1 interferons (IFN-I) are of increasing interest across a wide range of autoimmune rheumatic diseases. Historically, research into their role in rheumatoid arthritis (RA) has been relatively neglected, but recent work continues to highlight a potential contribution to RA pathophysiology.Recent findings: We emphasise the importance of disease stage when examining IFN-I in RA and provide an overview on how IFN-I may have a direct role on a variety of relevant cellular functions. We explore how clinical trajectory may be influenced by increased IFN-I signalling, and also, the limitations of scores composed of interferon response genes. Relevant environmental triggers and inheritable RA genetic risk relating to IFN-I signalling are explored with emphasis on intriguing data potentially linking IFN-I exposure, epigenetic changes, and disease relevant processes. Whilst these data cumulatively illustrate a likely role for IFN-I in RA, they also highlight the knowledge gaps, particularly in populations at risk for RA, and suggest directions for future research to both better understand IFN-I biology and inform targeted therapeutic strategies.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"37-52"},"PeriodicalIF":5.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10787895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138486919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions. 类风湿关节炎的多发病:文献综述及未来发展方向。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-01-01 Epub Date: 2023-11-23 DOI: 10.1007/s11926-023-01121-w

Jonathan Katz, Christie M Bartels

{"title":"Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions.","authors":"Jonathan Katz, Christie M Bartels","doi":"10.1007/s11926-023-01121-w","DOIUrl":"10.1007/s11926-023-01121-w","url":null,"abstract":"Purpose of review: To offer a narrative review of literature and an update on rheumatoid arthritis (RA) multimorbidity research over the past five years as well as future directions.Recent findings: Patients with RA experience higher prevalence of multimorbidity (31-86% vs 18-71% in non-RA) and faster accumulation of comorbidities. Patients with multimorbidity have worse outcomes compared to non-RA multimorbid patients and RA without multimorbidity including mortality, cardiac events, and hospitalizations. Comorbid disease clusters often included: cardiopulmonary, cardiometabolic, and depression and pain-related conditions. High-frequency comorbidities included interstitial lung disease, asthma, chronic obstructive pulmonary disease, cardiovascular disease, fibromyalgia, osteoarthritis, and osteoporosis, thyroid disorders, hypertension, and cancer. Furthermore, patients with RA and multimorbidity are paradoxically at increased risk of high RA disease activity but experience a lower likelihood of biologic use and more biologic failures. RA patients experience higher prevalence of multimorbidity and worse outcomes versus non-RA and RA without multimorbidity. Findings call for further studies.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"24-35"},"PeriodicalIF":5.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis. 抗中性粒细胞细胞质抗体相关血管炎中的心血管疾病。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-01-01 Epub Date: 2023-11-28 DOI: 10.1007/s11926-023-01123-8

Matthew Sayer, Gavin B Chapman, Matthew Thomas, Neeraj Dhaun

{"title":"Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis.","authors":"Matthew Sayer, Gavin B Chapman, Matthew Thomas, Neeraj Dhaun","doi":"10.1007/s11926-023-01123-8","DOIUrl":"10.1007/s11926-023-01123-8","url":null,"abstract":"Purpose of review: Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a rare, multisystem, autoimmune disease characterised by microvascular inflammation. Over the past 20 years, advances in immunological management have improved short-term patient outcomes. Longer-term patient outcomes remain poor with cardiovascular disease now the leading cause of death in AAV. Here, we examine the potential pathways that contribute to the increased risk of cardiovascular disease in AAV and the current evidence to manage this risk.Recent findings: The incidence of cardiovascular disease in AAV exceeds that expected by traditional risk factors alone, suggesting a contribution from disease-specific factors. Similarly, it is unclear how different immunosuppressive therapies contribute to and modify cardiovascular risk, and there is a paucity of data examining the efficacy of traditional cardioprotective medications in AAV. There is a lack of evidence-based cardiovascular risk assessment tools and cardioprotective therapies in patients with AAV which should be addressed to improve long-term outcomes.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"12-23"},"PeriodicalIF":5.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease and Treatment-Specific Complications of Behçet Syndrome. behet综合征的疾病和治疗特异性并发症。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-01-01 Epub Date: 2023-11-23 DOI: 10.1007/s11926-023-01124-7

Sinem Nihal Esatoglu, Yesim Ozguler, Gulen Hatemi

引用次数: 0

Synovial Tissue Insights into Heterogeneity of Rheumatoid Arthritis 滑膜组织揭示类风湿关节炎的异质性

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2023-12-29 DOI: 10.1007/s11926-023-01129-2

Anna Helena Jonsson

{"title":"Synovial Tissue Insights into Heterogeneity of Rheumatoid Arthritis","authors":"Anna Helena Jonsson","doi":"10.1007/s11926-023-01129-2","DOIUrl":"https://doi.org/10.1007/s11926-023-01129-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3>Rheumatoid arthritis is one of the most common rheumatic and autoimmune diseases. While it can affect many different organ systems, RA primarily involves inflammation in the synovium, the tissue that lines joints. Patients with RA exhibit significant clinical heterogeneity in terms of presence or absence of autoantibodies, degree of permanent deformities, and most importantly, treatment response. These clinical characteristics point to heterogeneity in the cellular and molecular pathogenesis of RA, an area that several recent studies have begun to address.<h3 data-test=\"abstract-sub-heading\">Recent Findings</h3>Single-cell RNA-sequencing initiatives and deeper focused studies have revealed several RA-associated cell populations in synovial tissues, including peripheral helper T cells, autoimmunity-associated B cells (ABCs), and NOTCH3+ sublining fibroblasts. Recent large transcriptional studies and translational clinical trials present frameworks to capture cellular and molecular heterogeneity in RA synovium. Technological developments, such as spatial transcriptomics and machine learning, promise to further elucidate the different types of RA synovitis and the biological mechanisms that characterize them, key elements of precision medicine to optimize patient care and outcomes in RA.<h3 data-test=\"abstract-sub-heading\">Summary</h3>This review recaps the findings of those recent studies and puts our current knowledge and future challenges into scientific and clinical perspective.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"25 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139064234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits 如何使用 Janus 激酶抑制剂治疗类风湿关节炎？风险与益处的临床评估

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2023-12-16 DOI: 10.1007/s11926-023-01122-9

Fatima K. Alduraibi, Jasvinder A. Singh

{"title":"How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits","authors":"Fatima K. Alduraibi, Jasvinder A. Singh","doi":"10.1007/s11926-023-01122-9","DOIUrl":"https://doi.org/10.1007/s11926-023-01122-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3>To provide an updated understanding of risks and benefits of Janus kinase inhibitors (JAKi) versus biologic disease-modifying antirheumatic drugs (bDMARDs) in the management of rheumatoid arthritis (RA).<h3 data-test=\"abstract-sub-heading\">Recent Findings</h3>Shared decision-making is needed in choosing between JAKi and bDMARDs. Cardiovascular disease, malignancy, and thromboembolic events guide this choice. In patients with active RA despite methotrexate use, tumor necrosis factor inhibitor is conditionally favored over JAKi for low-cardiovascular-risk patients and strongly favored in those with pre-existing cardiovascular disease or multiple cardiovascular risk factors. Suboptimal treatment of treatment-refractory RA patients may pose a greater absolute cardiovascular risk than with JAKi use. Use of aspirin and statin may be considered to reduce cardiovascular risk.<h3 data-test=\"abstract-sub-heading\">Summary</h3>New safety data on JAKi has redefined the treatment approach in RA. JAKi remains an important oral medication option in active RA despite treatment with bDMARDs, especially in those with low cardiovascular risk.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"71 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138689424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0